Drugs in development with potential to be first-in-class in 2016, by therapeutic area

This statistic shows the share of drugs in clinical development and regulatory review that have the potential to be first-in-class as of 2016, by therapeutic area. Some 86 percent of Alzheimer's disease drugs in clinical development had the potential to be first-in-class, as of 2016.

Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

July 2018

Region

United States

Survey time period

2016

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Top pharmaceutical drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.